Journal of Medical Economics study shows significant cost savings via MAF Test® – guided adjuvant bisphosphonate therapy for early-stage breast cancer

#PortfolioNews I Study shows that #MAFTest® developed by our #portfolio company #Ibiomotion may save €105M in early #breast #cancer care.

🔗 Press release - buff.ly/8pAhrip
📄 Full publication here: lnkd.in/d3aUWmpp

#Oncology #HealthEconomics #BreastCancer